| Literature DB >> 28272410 |
Xu Guan1,2, Senhao Jia3, Wei Chen4, Zheng Jiang2, Zheng Liu2, Yinggang Chen1, Guiyu Wang1, Xishan Wang1,2.
Abstract
Due to distinct biological behavior of mucinous adenocarcinoma (MAC) and signet ring cell cancer (SRC), the efficacy of radiotherapy on long-term outcome for rectal cancer (RC) patients with mucinous tumors is still unclear. Here, we identified 1808 RC patients with MAC/SRC from Surveillance, Epidemiology, and End-Results (SEER) database from 2004 to 2013. Patients were divided into two subgroups according to different therapeutic strategies, including surgery alone and surgery combined with radiotherapy. Kaplan-Meier methods and Cox regression models were used to access the influence of therapeutic strategy on long-term survival outcomes. The 5-year and 10-year cancer specific survival (CSS) were improved in stage II and III patients who underwent surgery and radiotherapy compared with patients who underwent surgery alone. These results were further confirmed following propensity score matching. In addition, radiotherapy was deemed as independent good prognostic factor in patient with MAC/SRC. In subgroup analysis, the result also demonstrated that long-term survival was improved following radiotherapy. However, there was no prognostic difference between preoperative and postoperative radiotherapy. In conclusion, radiotherapy could improve survival for RC patients with MAC and SRC, but only for patients in stage II and III. This finding supported the application of radiotherapy in clinical practice.Entities:
Mesh:
Year: 2017 PMID: 28272410 PMCID: PMC5341068 DOI: 10.1038/srep43821
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics among RC patients with MAC/SRC.
| Characteristics | Surgery alone N = 452 | Surgery combined with radiotherapy N = 1356 | P | ||
|---|---|---|---|---|---|
| Age (Years) | <0.001 | ||||
| <70 | 225 | 49.8% | 1032 | 76.1% | |
| ≥70 | 227 | 50.2% | 324 | 23.9% | |
| Gender | 0.004 | ||||
| Male | 268 | 59.3% | 904 | 66.7% | |
| Female | 184 | 40.7% | 452 | 33.3% | |
| Race | 0.480 | ||||
| Black | 40 | 8.8% | 132 | 9.7% | |
| White | 374 | 82.8% | 1088 | 80.3% | |
| Other | 38 | 8.4% | 136 | 10.0% | |
| Year of diagnosis | 0.145 | ||||
| 2004–2008 | 275 | 60.8% | 772 | 56.9% | |
| 2009–2013 | 177 | 39.2% | 584 | 43.1% | |
| AJCC Stage | <0.001 | ||||
| Stage I | 126 | 27.9% | 101 | 7.4% | |
| Stage II | 141 | 31.2% | 410 | 30.2% | |
| Stage III | 185 | 40.9% | 845 | 62.4% | |
| AJCC T stage | <0.001 | ||||
| T1/T2 | 160 | 35.4% | 173 | 12.8% | |
| T3/T4 | 292 | 64.6% | 1183 | 87.2% | |
| AJCC N stage | <0.001 | ||||
| N0 | 267 | 59.1% | 511 | 37.7% | |
| N1/2 | 185 | 40.9% | 845 | 62.3% | |
| Grade | <0.001 | ||||
| Grade I/II | 318 | 70.4% | 790 | 58.3% | |
| Grade III/IV | 105 | 23.2% | 399 | 29.4% | |
| Unknown | 29 | 6.4% | 167 | 12.3% | |
| Surgical approach | <0.001 | ||||
| Sphincter preserving surgery | 342 | 75.7% | 906 | 66.8% | |
| Abdominoperineal resection | 110 | 24.3% | 450 | 33.2% | |
Figure 1Trends of patient proportions according to different therapeutic strategies.
Figure 2(A) Comparisons of CSS in all patients with MAC/SRC. (B) Comparisons of CSS in stage I patients with MAC/SRC. (C) Comparisons of CSS in stage II patients with MAC/SRC. (D) Comparisons of CSS in stage III patients with MAC/SRC.
Figure 3Survival comparisons between surgery alone group and surgery combined with radiotherapy group in subgroup analysis.
Characteristics among RC patients with MAC/SRC after propensity score matching.
| Characteristics | Surgery alone N = 273 | Surgery combined with radiotherapy N = 273 | P | ||
|---|---|---|---|---|---|
| Age (Years) | 0.028 | ||||
| <70 | 156 | 57.1% | 181 | 66.3% | |
| ≥70 | 117 | 42.9% | 92 | 33.7% | |
| Gender | 0.096 | ||||
| Male | 157 | 57.5% | 176 | 64.5% | |
| Female | 116 | 42.5% | 97 | 35.5% | |
| Race | 0.809 | ||||
| Black | 30 | 11.0% | 27 | 9.9% | |
| White | 217 | 79.5% | 223 | 81.7% | |
| Other | 26 | 9.5% | 23 | 8.4% | |
| AJCC Stage | 1 | ||||
| Stage I | 24 | 8.8% | 24 | 8.8% | |
| Stage II | 142 | 52.0% | 142 | 52.0% | |
| Stage III | 107 | 39.2% | 107 | 39.2% | |
| AJCC T stage | 1 | ||||
| T1/T2 | 49 | 17.9% | 49 | 17.9% | |
| T3/T4 | 224 | 82.1% | 224 | 82.1% | |
| AJCC N stage | 1 | ||||
| N0 | 165 | 60.4% | 165 | 60.4% | |
| N1/2 | 108 | 39.6% | 108 | 39.6% | |
| Grade | 0.001 | ||||
| Grade I/II | 206 | 75.5% | 171 | 62.6% | |
| Grade III/IV | 52 | 19.0% | 67 | 24.5% | |
| Unknown | 15 | 5.5% | 35 | 12.8% | |
| Surgical approach | 0.626 | ||||
| Sphincter preservation surgery | 204 | 74.7% | 199 | 72.9% | |
| Abdominoperineal resection | 69 | 25.3% | 74 | 27.1% | |
Figure 4(A) Comparisons of CSS in patients with MAC/SRC after propensity score matching. (B) Comparisons of CSS in stage I patients with MAC/SRC after propensity score matching. (C) Comparisons of CSS in stage II patients with MAC/SRC after propensity score matching. (D) Comparisons of CSS in stage III patients with MAC/SRC after propensity score matching.
Univariate and multivariate analyses for RC patients with MAC/SRC.
| Characteristic | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR [95% CI] | P | HR [95% CI] | P | ||
| Gender | Female | 1 | 0.728 | ||
| Male | 1.028 [0.879–1.203] | ||||
| <70 | 1 | 0.179 | |||
| ≥70 | 1.115 [0.951–1.306] | ||||
| Race | White | 1 | 0.380 | ||
| Black | 0.981 [0.755–1.276] | ||||
| Others | 1.190 [0.927–1.528] | ||||
| AJCC Stage | Stage I | 1 | 0.015 | 1 | 0.037 |
| Stage II | 1.455 [1.127–1.877] | 1.743 [1.135–2.676] | |||
| Stage III | 1.301 [1.018–1.662] | 1.670 [1.113–2.507] | |||
| AJCC T stage | T1/T2 | 1 | 0.006 | 1 | 0.292 |
| T3/T4 | 1.322 [1.084–1.613] | 1.195 [0.858–1.665] | |||
| AJCC N stage | N0 | 1 | <0.001 | 1 | <0.001 |
| N1/2 | 1.459 [1.250–1.702] | 1.533 [1.300–1.809] | |||
| Grade | Grade I/II | 1 | 0.319 | ||
| Grade III/IV | 1.110 [0.937–1.314] | ||||
| Surgical approach | Sphincter preserving surgery | 1 | <0.001 | 1 | <0.001 |
| Abdominoperineal resection | 1.451 [1.242–1.696] | 1.380 [1.177–1.618] | |||
| Treatment strategy | Surgery alone | 1 | 0.001 | 1 | <0.001 |
| Surgery combined with radiotherapy | 0.759 [0.644–0.895] | 0.496 [0.404–0.608] | |||
Figure 5Survival comparisons between patients treated with preoperative radiotherapy and patients treated with postoperative radiotherapy.